Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes (NCT03929601)
🩺 Plain-English Summary (8th-Grade Level)
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab-pvvr compared to those treated with Rituximab-pvvr and placebo 24 months after enrollment.
Who can join: Review the eligibility criteria below.
Location: Childrens Hospital of Orange County — Orange, California
Age range: 8 Years to 45 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Childrens Hospital of Orange County — Orange, California
- Stanford University — Palo Alto, California
- University of California San Francisco — San Francisco, California
- Barbara Davis Center for Childhood Diabetes — Aurora, Colorado
- Yale University — New Haven, Connecticut
- University of Florida — Gainesville, Florida
- University of Miami — Maimi, Florida
- Indiana University - Riley Hospital for Children — Indianapolis, Indiana
- The Children's Mercy Hospital — Kansas City, Kansas
- Joslin Diabetes Center — Boston, Massachusetts
- University of Minnesota — Minneapolis, Minnesota
- Columbia University — New York, New York
- University of Pittsburg — Pittsburgh, Pennsylvania
- Sanford Children's Specialty Clinic — Sioux Falls, South Dakota
- Vanderbilt Eskind Diabetes Center — Nashville, Tennessee
- University of Texas Southwestern — Dallas, Texas
- Benaroya Research Institute — Seattle, Washington
- Queensland Children's Hospital — South Brisbane, Queensland
- Walter and Eliza Hall Institute of Medical Research — Melbourne, Victoria
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Type 1 Diabetes Mellitus
- Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D) — Chicago, Illinois
- A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation — Chicago, Illinois
- Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus — Walnut Creek, California
- Triple Therapy in T1DM — Williamsville, New York
- Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2) — Toronto, British Columbia
Explore by condition: All Type 1 Diabetes Mellitus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.